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Abstract. 
One form of neurotoxicity is the principal and dose-limiting toxicity of oxaliplatin. It has 
been observed that the incidence of oxaliplatin-induced severe neurotoxicity has varied from 
12% to 18% in different clinical trials. Oxaliplatin-induced neuropathy can be divided into 
two distinct syndromes. The first is a unique syndrome of acute, transient peripheral nerve 
hyperexcitability occurring shortly after the infusion of oxaliplatin. The second one is a pe-
ripheral sensory neuropathy occurring mainly in the distal extremities with symptoms similar 
to those caused by cisplatin. It may last for several months, and results in a severe disturbance 
of neurologic function, and has a significant impact on oxaliplatin treatment. Various strate-
gies have been proposed to prevent or treat oxaliplatin-induced neurotoxicity, including the 
stop-and-go concept, calcium and magnesium infusions, antiepileptic drugs, glutathione, 
xaliproden, NSAIDs, glutamine, and opioid drugs. In this article, the authors focus on the 
mechanisms of peripheral neuropathy induced by oxaliplatin, the role of glutamine in the 
management of oxaliplatin-neuropathy, genomic polymorphisms involved in an altered sus-
ceptibility to opioid drugs in managing oxaliplatin-induced neuropathic pain, and the use of 
nerve conduction velocity studies in objectively assessing oxaliplatin-induced neuropathy. 
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綜合評論  
Oxaliplatin 神經毒性治療方面的進展：聚焦在麩醯胺酸以及利用基因
體多型性來預測鴉片類藥物於 Oxaliplatin 疼痛性神經病變之療效 
王緯書 
國立陽明大學 醫學系 
國立陽明大學附設醫院 內科部 
中文摘要 
  神經毒性是 oxaliplatin 治療期間最常見的副作用。根據不同的臨床研究報告，
oxaliplatin 所引起的嚴重神經毒性的機率約為 12%至 18%。依症狀之不同，oxaliplatin 神
經毒性可分為兩類。第一類是相當特殊、急性的、暫時性的週邊神經過度敏感現象，通
常在給藥後幾個小時內就會發生。第二類與 cisplatin 引起的神經毒性類似，係發生於肢
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 端末稍的感覺神經病變。這類型的神經毒性會持續數個月，導致神經功能明顯失常，並
有可能會影響後續的治療。目前已有幾種策略用來預防或治療 oxaliplatin 引起的神經毒
性，包括「打打停停」（stop-and-go）策略、鈣及鎂離子的輸注、抗癲癇藥物、glutathione、
xaliproden、非類固醇消炎藥、麩醯胺酸、以及鴉片類藥物等。於本文中，作者聚焦於
oxaliplatin 導致週邊神經病變的機轉、麩醯胺酸用於 oxaliplatin 神經毒性的療效、基因體
多型性所導致鴉片類藥物於 oxaliplatin 疼痛性神經病變療效的差異，以及可否利用神經
傳導速率檢查來客觀評估 oxaliplatin 所引起的神經毒性。 
 
關鍵字: oxaliplatin、神經毒性、麩醯胺酸、基因體多型性、鴉片類藥物 
INTRODUCTION 
Oxaliplatin, a cytotoxic agent from the diamino-
cyclohexane platinum family, exerts its cytotoxic ef-
fects through the formation of DNA adducts that 
block both DNA replication and transcription in ac-
tively dividing cells [1]. In combination with 5- 
fluorouracil (5-FU) and folinic acid (FA), oxaliplatin 
is effective in the treatment of metastatic colorectal 
cancer patients [2]. Furthermore, the combination of 
oxaliplatin and 5-FU/FA has been proven to be bene-
ficial in enabling surgical removal of previously unre-
sectable liver metastases [3]. In an adjuvant setting for 
stage II/III CRC patients, oxaliplatin plus 5-FU/FA 
significantly improved survival [4]. One manifestation 
of neurotoxicity is the principal and dose-limiting 
toxicity of oxaliplatin, and the incidence of oxali-
platin-induced severe neurotoxicity has varied from 
12% to 18% in different clinical trials [4-6]. 
Oxaliplatin-induced neuropathy consists of two 
distinct syndromes. The first one occurs soon after 
oxaliplatin is infused, and is a unique syndrome of 
acute, transient peripheral nerve hyperexcitability. 
Oxaliplatin is the only platinum complex to produce 
this type of neuropathy [7]. This form of neuropathy 
usually occurs at low total cumulative doses and can 
be triggered or exacerbated by exposure to cold. Pa-
tients may experience paresthesias and dysesthesias of 
the hands and feet, as well as the larynx and jaw. 
These symptoms usually occur within hours of expo-
sure and are reversible over the following hours and 
days; they generally do not require that treatment be 
discontinued [7]. The second syndrome is a peripheral 
sensory neuropathy occurring mainly in the distal ex-
tremities with symptoms similar to those caused by 
cisplatin [8]. Development of this form of neuropathy 
is correlated with the cumulative dose of oxaliplatin. It 
may last for several months, resulting in a severe dis-
turbance of neurologic function, and has a significant 
impact on oxaliplatin treatment [8]. 
Various strategies have been proposed to prevent 
or treat oxaliplatin-induced neurotoxicity. The “stop- 
and-go” concept uses the predictability and reversibil-
ity of neurologic symptoms of oxaliplatin to allow 
patients to stay on an oxaliplatin-containing first-line 
therapy for a prolonged period [6]. Several neuro-
modulatory agents such as calcium and magnesium 
infusions [9], antiepileptic drugs like carbamazepine 
and gabapentin [10], amifostine [11], and glutathione 
[12] have demonstrated some activity in the prophy-
laxis and treatment of oxaliplatin-induced acute neu-
ropathy. The use of Xaliproden, a selective and potent 
5-HT1A receptor agonist, has led to encouraging re-
sults in reducing the intensity of peripheral neuropathy, 
without altering the effectiveness of the oxaliplatin in 
advanced colorectal cancer [13]. In this article, we 
discuss the mechanisms of neuropathy induced by ox-
aliplatin, the role of glutamine in reducing oxali-
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 platin-induced neuropathy, genomic polymorphisms 
involved in altered susceptibility to opioid drugs in 
managing oxaliplatin-induced neuropathic pain, and 
the use of nerve conduction velocity studies on objec-
tively assessing oxaliplatin-neuropathy. 
 
MECHANISMS OF PERIPHERAL 
NEUROPATHY INDUCED BY 
OXALIPLATIN 
Chemotherapy-induced peripheral neuropathy 
(CIPN) is common in patients treated with several 
classes of chemotherapeutic agents including taxanes, 
vinca alkaloids, and platinum-based compounds. The 
mechanism of platinum drug neurotoxicity involves 
drug accumulation within the peripheral nervous sys-
tem, especially in the dorsal root ganglia [14]. The use 
of glutathione can prevent the initial accumulation of 
platinum adducts in the dorsal root ganglia and there-
by reduce neurotoxicity [12]. One possible mechanism 
underlying oxaliplatin-induced neuropathy is that an 
oxaliplatin metabolite, such as oxalate, may alter the 
properties of voltage-gated sodium channels or slow 
down the clearance of platinum compounds from the 
peripheral nervous system [15,16]. Therefore, using 
calcium and magnesium infusions to chelate oxalate 
may reduce the incidence and intensity of oxali-
platin-induced neuropathies [9]. Prophylactic use of a 
neurotrophic agent, xaliproden, was shown to reduce 
the risk of grade 3-4 peripheral sensory neurotoxicity 
by 39% in metastatic colorectal cancer patients treated 
with oxaliplatin [13,17]. 
In contrast to chronic cumulative neuropathy in-
duced by cisplatin, oxaliplatin induces symptoms with 
cold allodynia and a rapid onset hyperexcitability ear-
ly in the course of treatment [18]. Interestingly, oxali-
platin-induced mechanical hyperalgesia can be antag-
onized by antioxidants, supporting a role for reactive 
oxygen species (ROS) production in oxaliplatin-  
induced painful neuropathy [19]. Clinically, the use of 
glutathione protects against CIPN by defending 
against oxidative injury [12]. In addition, glutathione 
S-transferase P1 (GSTP1) contributes to the detoxifi-
cation of cytotoxic compounds, including ROS, which 
may alter the efficacy and cumulative neurotoxicity of 
chemotherapy [20]. Nonsteroidal anti-inflammatory 
drugs (NSAIDs) have a modest effect in relieving 
neuropathy symptoms [21], but it remains unclear if 
inflammation is an important component of chemo-
therapy-induced painful neuropathy. Tricyclic antide-
pressants, including nortriptyline and amitriptyline [22, 
23], and anticonvulsants, including carbamazepine 
and oxcarbazepine [24,25], have been suggested as 
therapeutic options for neuropathic pain; however, 
there are few data to support their use in chemothera-
py-induced painful neuropathy. Therefore, identifica-
tion of alternative treatment strategies would be help-
ful for patients afflicted with chemotherapy-induced 
painful neuropathy. 
 
THE ROLE OF GLUTAMINE IN 
REDUCING OXALIPLATIN-  
INDUCED NEUROPATHY 
Glutamine, the most abundant amino acid in blood, 
constitutes 60% of the total free amino acid pool in 
skeletal muscle [26]. Glutamine is also a gluconeo-
genic nonessential amino acid that is stored primarily 
in skeletal muscle and liver [26]. It contains two 
amine groups per molecule, playing an important role 
as a nitrogen transporter, and providing precursor ni-
trogen for the synthesis of purines and pyrimidines 
[27]. Glutamine is often depleted in stress states, such 
as malignancy; therefore, it becomes a “conditionally” 
essential amino acid during periods of stress [28]. It 
serves as the primary carrier of nitrogen and is the 
main energy source for rapidly proliferating cells. 
Rapid proliferation of a tumor may deplete glutamine 
stores and subsequently lead to cancer-related ca-
chexia [29]. In patients with malignant diseases, 
marked glutamine depletion develops over time, and 
the development of cachexia is accompanied by mas-
sive depletion of glutamine in skeletal muscle. This 
results in a negative impact on the function of host 
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 tissues that are dependent upon adequate stores of 
glutamine for optimal functioning [29]. 
Clinically, glutamine supplements may reduce the 
severity of peripheral neuropathy in metastatic breast 
cancer patients receiving high-dose paclitaxel and 
hematopoietic stem cell transplantation [30]. These 
facts support a possible therapeutic role for glutamine 
in the prevention of damage to normal tissues, includ-
ing peripheral nerves, during chemotherapy. Studies 
have indicated that glutamine supplementation is 
well-tolerated and potentially effective in preventing 
side effects for patients receiving high-dose chemo-
therapy and bone marrow transplantation [31]. Gluta-
mine can also protect against doxorubicin-induced 
cardiac toxicity [32] and prevents atrophy of the intes-
tinal mucosa in patients receiving total parenteral nu-
trition [33]. Preliminary animal studies suggest that 
glutamine may prevent neurotoxicity caused by vin-
cristine [34], cisplatin, and paclitaxel [35]. Clinically, 
paclitaxel-induced myalgia and arthralgia have been 
successfully reduced by glutamine in breast cancer 
patients [36]. And glutathione, a byproduct of gluta-
mine metabolism has been identified to protect pa-
tients from oxaliplatin-induced neuropathy [12]. In a 
study, supplementation with glutamine significantly 
reduces the severity of neuropathy and the need for 
dose reduction of oxaliplatin in colorectal cancer pa-
tients [37]. These properties may increase the thera-
peutic index of oxaliplatin. A study of circulating 
nerve growth factor (NGF) levels in patients treated 
with neurotoxic chemotherapeutic agents found that 
peripheral neuropathy worsens as serum levels of 
NGF declined [38], and the administration of NGF 
prevents paclitaxel-induced neuropathy in an animal 
model [39]. Because glutamine is known to upregulate 
NGF mRNA expression in an animal model [40], glu-
tamine supplements may prevent chemotherapy-  
induced neuropathy via upregulating the NGF level. 
On the other hand, it has also been hypothesized that 
high systemic levels of glutamine may downregulate 
the conversion of glutamine to an excitatory neuro-
peptide, glutamate, which may also account for the 
reduced symptoms observed in patients receiving glu-
tamine [41]. 
 
OPIOID DRUGS IN RELIEVING 
OXALIPLATIN-INDUCED  
PAINFUL NEUROPATHY 
Opioids have long been inappropriately judged in-
effective for the treatment of neuropathic pain [42]; 
however, in properly selected patients, opioids may be 
a good option for treating painful neuropathy. For 
example, the benefit of oxycodone in treating diabetic 
neuropathy has been demonstrated [43], and the use of 
tramadol may effectively relieve pain and allodynia in 
patients with polyneuropathy [44]. Tramadol is a cen-
trally-acting analgesic that binds mu-opioid receptors 
and inhibits reuptake of norepinephrine and serotonin 
at synapses. Acetaminophen is a centrally-acting an-
algesic that appears to relieve pain through both spinal 
and supraspinal levels. The combination of tramadol 
and acetaminophen may relieve pain through multiple 
pathways; this combination, in a fixed ratio of ap-
proximately 1:8, has been found to have a synergistic 
effect in animal models [45]. In a randomized place-
bo-controlled trial, tramadol/acetaminophen 37.5 mg/ 
325 mg combination tablets (Ultracet) were effective 
in relieving fibromyalgia pain [46]. Ultracet is effec-
tive in the treatment of chronic low back pain [47], 
osteoarthritis pain in subjects receiving a COX-2 in-
hibitor [48], and breakthrough pain in cancer patients 
[49]. In a study, the authors demonstrate that Ultracet 
is effective in relieving oxaliplatin-induced painful 
neuropathy [50]. 
In addition to Ultracet, methadone is also effective 
in the treatment of CIPN. Methadone, a potent 
mu-opioid agonist, has a number of unique properties 
that make it the “opioid of choice” for the treatment of 
persistent neuropathic pain [51]. The property of 
methadone sets it apart from other opioids including 
antagonism to NMDA (N-methyl-D-aspartate) recep-
tors, a known modulator of neuropathic pain [52]. 
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 Moreover, methadone may inhibit the reuptake of 
norepinephrine and serotonin, leading to improved 
analgesia in neuropathic pain [53]. In an animal model, 
methadone produces an analgesic effect on peripheral 
neuropathy induced by paclitaxel [54]. Clinically, 
methadone appears to be useful in the management of 
intractable neuropathic non-cancer pain [55]. In some 
cases, opioid rotation is required for avoiding intoler-
able side effects or achieving improved pain control. 
Clinical trials have demonstrated successful rotation 
to methadone from other strong opioids in the setting 
of intolerable side effects and inadequate analgesia 
despite dose escalation [56], and outpatient methadone 
initiation and rotation has been shown effective, safe, 
with low side effect profiles for cancer pain treatment 
[57]. Based on these findings, the use of methadone 
with opioid rotation appears to be a good option for 
managing intractable neuropathic pain. Further studies 
are warranted. 
 
GENOMIC POLYMORPHISMS 
INVOLVED IN ALTERED  
SUSCEPTIBILITY TO OPIOID 
DRUGS IN MANAGING  
OXALIPLATIN-INDUCED  
PAINFUL NEUROPATHY 
Ultracet has been shown effective in relieving ox-
aliplatin-induced painful neuropathy; however, there 
remains a subgroup of patients who do not respond to 
Ultracet [50]. Thus, there is significant interest in 
identifying factors predictive of sensitivity to drugs 
for relieving pain. Genetic polymorphisms involved in 
the mu-opioid receptor have been associated with an 
altered pain threshold and susceptibility to opioid 
drugs. The most common coding region single nucle-
otide polymorphism in the OPRM1 gene is the A118G 
(A to G substitution) polymorphism [58]. This poly-
morphism results in the substitution of the amino acid 
asparagine with aspartate at position 40, and has been 
found to be associated with functional effects that may 
reduce morphine efficacy [59]. For patients with pain 
caused by malignant diseases, the A118G polymor-
phism in OPRM1 significantly increases morphine 
requirements [60]. Individuals homozygous for the 
mutant-type 118G allele required more intravenous 
patient-controlled analgesia consumption following 
total abdominal hysterectomy [61]. For patients un-
dergoing painful cosmetic surgery, a diminished anal-
gesic effect of fentanyl was shown in individuals with 
118G allele variants [62]. The mu-opioid receptor is 
also the primary site of action for several endogenous 
opioid peptides [63], and altered OPRM1 genotype 
has been associated with vulnerability for developing 
opiate addiction. One study has shown an increased 
affinity and potency of beta-endorphin on the homo-
zygous G allelic receptor, resulting in increased vul-
nerability for developing addiction [64]. In a study, 
patients with oxaliplatin-induced painful neuropathy 
who had OPRM1-118 G allele variants had a reduced 
analgesic effect to Ultracet [50], which is compatible 
with previous studies. The pre- and post-treatment 
VAS scores for individuals with G allele variants were 
3.1 and 2.6, respectively; but for patients with the AA 
genotype, these figures were were 3.0 and 0.9, respec-
tively. In addition, the requirement for rescue analge-
sia was also higher for patients with G allele variants 
[50]. 
Clinically, different individuals have different 
sensitivity to opioid drugs, suggesting potential varia-
bility in opioid receptors or their down-stream effec-
tors. Opioid receptors are the primary sites of action of 
opioid analgesics which mediate multiple pharmaco-
logic effects. Among subpopulations of opioid recep-
tors, the mu receptor modulates predominately su-
praspinal analgesia [65], and polymorphisms of the 
mu-opioid receptor gene may contribute to altered 
susceptibility to opioid drugs. For example, the 
A118G polymorphism of OPRM1 increases opioid 
requirements in patients with pain caused by various 
etiologies [60-62]. In addition, the short tandem re-
peats in the 5' flanking and 3' untranslated regions of 
OPRM1 have been associated with altered sensitivity 
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 to morphine-induced antinociception [66]. However, 
the C17T polymorphism of OPRM1, the second most 
common coding region variant of the mu-opioid re-
ceptor gene in Caucasian populations, has no influ-
ence in ligand binding or ligand-mediated signaling 
[67]. 
The frequency of OPRM1 A118G polymorphism 
varies widely across population groups. Compared to 
Caucasian populations, a remarkably higher preva-
lence (68.7%) of OPRM1 118G allele variants, in-
cluding A/G (58.3%) and G/G (10.4%), was noted in 
the patients in Asian populations [64]. Ethnic differ-
ences have a profound influence on the response and 
toxicity of chemotherapy. For example, because of a 
higher prevalence of EGFR mutations, gefitinib is 
very effective in Asian patients with non-small cell 
lung cancer [68]. The UGT1A1*28 polymorphism is 
rare in Asian populations, leading to a decreased risk 
of developing severe neutropenia after treatment with 
irinotecan [69]. In a study conducted in Singapore, the 
prevalence of OPRM1 codon 118 G allele variants 
was 54.0% in Asian populations [70]. But in Cauca-
sian populations, the prevalence of 118 G allele vari-
ants was only 21.1% [64]. In addition, the C17T pol-
ymorphism, the second most common coding region 
variant of OPRM1 in Caucasian populations, has not 
been found in Chinese populations [71]. These results 
suggest that Asian populations might have an altered 
function in the mu-opioid receptor and a reduced re-
sponse to opioid drugs. 
Varied CYP2D6 activity might also affect the an-
algesic efficacy of Ultracet. Tramadol owes its phar-
macological activity through biotransformation into an 
active metabolite, O-demethyltramadol (M1), via cy-
tochrome P450 2D6 (CYP2D6) in the liver [72]. M1 
has remarkably higher activity than tramadol; moreo-
ver, M1 is also a potent monoamine reuptake inhibitor 
that may enhance the analgesic effects of tramadol 
through the inhibition of neuronal reuptake of nora-
drenalin and serotonin [73]. Different CYP2D6 geno-
types results in varied CYP2D6 activity, from very 
low (poor metabolizer) to extensively high (ultra-rapid 
metabolizer) [74], and the activity of CYP2D6 signif-
icantly influences the pharmacokinetics of tramadol 
and M1; therefore, it is anticipated that the CYP2D6 
genotype contributes to the individual variability of 
Ultracet efficacy. 
 
THE USE OF NERVE  
CONDUCTION VELOCITY 
STUDIES IN OBJECTIVELY 
ASSESSING OXALIPLATIN-  
INDUCED NEUROPATHY 
Because the symptoms of neuropathy are usually 
subjective, a precise clinical evaluation including de-
tailed history-taking as well as physical examination is 
crucial for detecting the occurrence of neuropathy. In 
fact, the grading systems we commonly used in daily 
practice or clinical trials for evaluating CIPN do not 
include electrophysiological studies. However, elec-
trophysiological studies remain useful in objectively 
assessing CIPN [75-77]. It has been shown that the 
damage to the nucleolus of ganglionic sensory neu-
rons of rats treated with various platinum drugs is 
closely linked to the alteration of nerve conduction 
velocity (NCV) [75]. Interestingly, oxaliplatin reduces 
NCV mainly in peripheral and sensory nerves without 
affecting central or motor nerve conductions [76] 
which were compatible with the clinical manifesta-
tions. Clinically, the severity of neurological symp-
toms often correlated with electrophysiological find-
ings [77]. In a study on the efficacy of oxcarbazepine 
in preventing oxaliplatin neurotoxicity, the authors 
demonstrated that between-group (patients receiving 
oxcarbazepine versus control group) comparison of 
the median changes in amplitude of sensory action 
potentials (a-SAP) revealed significant differences in 
two of the three sensory nerves tested, thereby favor-
ing oxcarbazepine administration [25]. In previous 
studies on the topic of CIPN, the severity of clinical 
symptoms and signs correlated well with electrophys-
iological findings [78,79]. Another study also revealed 
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 a significant longitudinal decrease in all the a-SAPs 
examined during treatment with oxaliplatin-based 
chemotherapy [79]. 
Sometimes, although NCV can be affected by ox-
aliplatin treatment, the severity of neuropathy does not 
always correlate to the findings in nerve conduction 
studies. For example, the symptoms of neuropathy 
could be remarkably reduced after discontinuation of 
oxaliplatin treatment; however, abnormalities of NCV 
were shown to persist [80]. Cascinu et al. demon-
strated that sensory nerve conduction was significant-
ly affected by oxaliplatin only in patients receiving 
placebo, but not in those receiving glutathione [12]. In 
a previous study, no between group differences were 
found in NCV of patients received glutamine supple-
ment or not, although those who received glutamine 
had a remarkably lower incidence of grade 3/4 neu-
ropathy [37]. In another study, although a significant 
correlation was found in NCV abnormalities and the 
severity of neurological symptoms (33.3% vs. 3.4%, 
p<0.01), 1 patient (3.4%) with a normal NCV devel-
oped severe neuropathies and 26 patients (66.7%) had 
an impaired NCV without or with only mild neuro-
logical symptoms [81]. Therefore, a detailed history 
taking as well as physical examination remains very 
important for evaluating the development of neuropa-
thy because it is the “clinical symptoms” of neuropa-
thy that bother patients, not “NCV data” themselves. 
 
SUMMARY 
The development of neuropathy during oxaliplatin 
treatment has a significant impact on patients’ quality 
of life. Several modalities have been shown to be ef-
fective in the management of oxaliplatin-neuropathy, 
including glutamine. The A118G polymorphism of the 
OPRM1, by altered function of the mu-opioid receptor 
and consequential analgesic efficacy to opioid drugs, 
could be a key determinant for decreased response to 
opioid drugs. NCV correlates well with the severity of 
neurological symptoms in patients treated with oxali-
platin, and the addition of NCV to a precise physical 
examination is helpful in objectively assessing oxali-
platin-induced neuropathy. 
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